Introduction
During development of new anti-cancer drugs, methods to assess early treatment effect and discriminate between responders and non-responders are widely needed. The use of positron emission tomography (PET) to discriminate between responders and non-responders early following treatment initiation is desirable. The PET technique allows for non-invasive characterization of biological functionality in tumor tissue. 39-deoxy-39-[18F]fluorothymidine ([18F]FLT) is used to assess cell proliferation in vivo by PET, by measuring the activity of thymidine kinase 1 (TK1) which is up-regulated in the S-phase of cell cycle [1] [2] [3] [4] [5] [6] . Uptake of [18F] FLT has in several pre-clinical models been shown to decrease following treatment with various chemotherapeutics much earlier than a response in tumor volume is evident [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . However, changes in [18F]FLT uptake following treatment are variable and dependent upon mode of action for the different chemotherapeutic drugs [7, [9] [10] [11] 13] .
APO866 is a new anti-tumor compound which inhibits nicotinamide phosphoribosyltransferase (NAMPT), an enzyme involved in the biosynthesis of NAD. APO866 inhibits biosynthesis of cellular NAD from niacinamide by inhibiting NAMPT. Reduction in cellular NAD levels leads to ATP depletion and apoptosis [17, 18] . Cancer cells have a high NAD turn over compared with normal cells. NAD is an important cofactor for poly(ADP-ribose) polymerase 1 (PARP1) which is involved in DNA repair and therefore cancer cells are more sensitive to NAMPT inhibition than normal cells. APO866 has anti-tumor effect in many tumor cells in vitro and several pre-clinical human xenograft tumor models [19, 20] . A clinical phase I study with APO866 has already been conducted [21] , and APO866 is currently in several clinical phase II studies.
APO866 treatment decreases cellular ATP content [17, 19] and ATP is a cofactor for TK1 [22] . We therefore hypothesized that [18F]FLT uptake would be influenced by APO866 treatment due to the decrease in ATP and possibly a change in tracer uptake could be used to predict treatment response at an early stage. 
Materials and Methods

Tumor Model
Animal care and all experimental procedures were performed under the approval of the Danish Animal Welfare Council (2006/ 561-1124). Female NMRI (Naval Medical Research Institute) nude mice (6-8 weeks old) were acquired from Taconic Europe (Lille Skensved, Denmark) and allowed to acclimatize for one week in the animal facility before any intervention was initiated. The human ovarian carcinoma cell line A2780 [23] (a gift from R. Ozols, Fox Chase Cancer Center Philadelphia, PA, USA) was used. A total of 10 7 cells in 100 mL medium mixed with 100 mL Matrixgel TM Basement Membrane Matrix (BD Biosciences, San Jose, CA, USA) were injected subcutaneously into the left and right flank respectively during anesthesia with 1:1 v/v mixture of HypnormH (Janssen Pharmaceutica, Beerse, Belgium) and DormicumH (Roche, Basel, Switzerland). The cell line has been tested free of mycoplasma. Cells were cultured in RPMI (Roswell Park Memorial Institute) medium 1640+ GlutaMAX (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal calf serum (Biological Industries, Israel) and 1% penicillin-streptomycin (Invitrogen) in 5% CO 2 at 37uC.
Experimental Design
Mice were divided into groups (n = 6-12 tumors per group) receiving either APO866 or vehicle treatment and [18F]FLT or [18F]FDG scans. Treatment was started at day 14-16 after implantation of tumor cells, where tumor volumes were on average 265 mm 3 . Mice in the treatment groups received APO866 (figure 1) in saline/PBS with 2% HP-b-CD and 9% propylene glycol at a dose of 15 mg/kg IP twice daily for 7 days. This is the maximum tolerated dose of APO866 and inhibits growth of the A2780 xenograft tumor model [20] [24] [25] [26] . In addition to the microCT measurement of tumor volume, tumor sizes were followed by external caliper measurements where tumor volume was calculated using the modified ellipsoidal formula K(length*width 2 ). At Day 7 tumors were excised and transferred to 280uC for Ki67 immunohistochemistry analysis. All tumors were weighted and tumor weight was correlated with both microCT and caliper determined tumor volume.
Synthesis of [18F]FLT and [18F]FDG
[18F]FLT was synthesized using 3-
thymine as precursor on a GE TracerLab MX Synthesizer as described earlier [7] . All reagents and [18F]FLT cassettes were purchased from ABX (Radeberg, Germany). [27] . One hour after tracer injection mice were anaesthetized with 3% sevoflurane (Abbott Scandinavia AB, Solna, Sweden) mixed with 35% O 2 in N 2 and fixed on a bed in presence of three fiducial markers allowing fusion of PET and CT pictures. A 10 min PET scan was acquired using a MicroPET Focus 120 (Siemens Medical Solutions, Malvern, PA, USA). After data acquisition, PET data were arranged into sinograms and subsequently reconstructed with the maximum a posteriori (MAP) reconstruction algorithm. The pixel size was 0.86660.86660.796 mm and in the center field of view the resolution was 1.4 mm full-width-at-half-maximum. The images were not corrected for attenuation or scatter.
Following the microPET scan, a microCT scan was acquired with a MicroCATH II system (Siemens Medical Solutions). A 7 minute and 10 seconds CT scan was performed with parameter settings: 360 rotation steps, tube voltage 60 kV, tube current 500 mA, binning 4 and exposure time 310 ms. The pixel size was 0.09160.09160.091 mm.
PET and microCT images were fused in the Inveon software (Siemens Medical Solutions). Before fusion region of interests (ROIs) were drawn on the CT pictures manually by qualitative assessment covering the whole tumors and subsequently tumor volume and tracer uptake, assessed by standard uptake values (SUV) mean and maximum, were generated by summation of voxels within the tomographic planes. SUV was defined as (C T *W)/D inj , where C T is radioactivity in the tissue, W is weight of the animal and D inj is injected dose. SUVmean gives information of the mean concentration of tracer and SUVmax is a measure of the voxel within the ROI which have the highest tracer concentration. For tumor volume measurements ROIs were drawn manually by delineation of the tumor boundary by qualitative assessment in several of the coronal planes on the microCT images. Summation of voxels from all the planes generated the tumor volume.
Ki67 Immunohistochemistry
After freezing at 280uC tissue samples were fixed in 4% neutral buffered formalin and subsequently embedded in paraffin. The anti-human Ki-67 clone MIB-1 (Dako cat.no F7268/FITC conjugated mouse antibody) was used. The reactions were detected using standard polymer technique with few modifications. Negative controls were performed by omission of primary antibody. Sections were dewaxed in xylene, rehydrated and pretreated before immunostaining. The slides were incubated with MIB-1 1:100 diluted in Power Block solution (BioGenex,cat. no. HK085-5K) for 30 min at room temperature. The sections were rinsed in TBST (365 minutes) and incubated with rabbit anti-FITC (Invitrogen, cat. no. The level of Ki67 present in the samples was measured as mean of three hot spots on one slide from each tumor. Hotspots were defined as areas with the highest Ki67 intensity and were identified by scanning the entire tumor slide in 106magnification. Ki67 positive cells were defined as cells with positive nucleus staining. The Ki67 staining index was defined as the number of Ki67 positive cells divided by the total number of tumor cells in an area on the 606magnification. Positive and negative controls from human tissue were placed on each slide for validation of the immunohistochemical procedure.
Statistical Analysis
Comparison of tumor volume between the treatment and control group were calculated using an unpaired student's t-test. For intra-group comparisons of tracer uptake ANOVA with Bonferroni post-hoc test was used. All data were tested to be normal distributed by means of Kolmogorov-Smirnov test. Correlations between SUVmax ratios and tumor growth were calculated using linear regression. Calculations were made in PASW 17.0 (IBM, Armonk, NY, USA). Data are reported as mean6SEM (unless stated otherwise) and P,0.05 was considered statistically significant.
Results
Tumor Growth of APO866 and Vehicle Treated A2780 Xenografts Correlations between SUVmax ratios, from baseline to 24 h, 48 h and Day 7 respectively, and tumor volume changes from baseline to Day 7 for the individual tumors were calculated. For 
Ki67 Immunohistochemistry
Expression of Ki67 protein measured by immunohistochemistry showed a significant correlation with [18F]FLT SUVmean (r 2 = 0.75; P,0.001). Differences in expression of Ki67 protein between the treatment (28.3%) and control group (52.5%) were significant (P = 0.022) (figure 7). Some of the treated tumors had 0% Ki67 protein expression. Treatment with APO866 for 7 days resulted in no observable Ki67 positive cells in the slides for these tumors.
Discussion
In this study we investigated the effect of APO866 treatment on tumor uptake of A measure of the maximal tracer uptake is often used when assessing treatment responses rather than the mean tracer uptake [28] . With SUVmax the most active metabolic region of the tumor is measured, and one advantage of this is that some of the volume delineation problems often found in SUVmean values is overcome. Much discussion has centered about if inhibiting the most active metabolic or proliferative regions with the anti-cancer treatment is likely to give the best treatment effect. Maximal uptake values are in several studies shown to be a prognostic factor for outcome [28] [29] [30] [31] [32] . In the present study we found that changes in SUVmax following treatment correlated better with later tumor volume effect than changes in SUVmean. Furthermore, we found a much greater decrease in [18F] FLT SUVmax values at Day 7 compared to SUVmean values.
Lower uptake of tracer at Day 7 compared to baseline for both [18F]FLT and [18F]FDG in the treatment groups was most likely not due to partial volume effect because of a decrease in tumor volume as the tumors did not shrink during the treatment. The changes in tracer uptake were therefore assumed to be due to physiologic changes in the tumor tissue which were further confirmed by the difference in the quantity of Ki67 positive cells between the treatment and control groups. Positive correlation between [18F]FLT uptake and the amount of Ki67 positive cells have earlier been reported by others [33] [34] [35] [36] .
APO866 is a relatively slow acting anti-cancer drug without any immediate cytotoxicity leading to ATP depletion and apoptosis [17, 19] . Since ATP is a co-factor for TK1, a decrease in ATP level will possibly decrease uptake of FLT 48 hours after treatment initiation were those which had the lowest increase in tumor volume at the end of the experiment. It indicates that we, in addition to finding a decrease in the whole treatment groups, on the individual tumor level already at 48 hours after treatment initiation were able to identify the tumors that responded best to the treatment as it were those that had the greatest change in SUVmax values.
In conclusion, we found a decrease in tumor [18F]FLT uptake following treatment with the nicotinamide phosphoribosyltransferase inhibitor APO866. After 7 days of treatment tumor uptake of [18F]FDG was half of baseline uptake. Additionally, we found that the tumors which responded best to the treatment were those that had the greatest change in both 
